Results of the multivariable analyses
| Parameter . | Disease-free survival . | Treatment-related mortality . | Relapse . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| RR . | 95% Cl . | Pvalue . | RR . | 95% Cl . | P value . | RR . | 95% Cl . | P value . | |
| First remission | 1.00 | NA | 1.00 | NA | 1.00 | NA | |||
| CR 2/3 | 1.38 | (0.64 -2.97) | .40 | 1.01 | (0.42-2.44) | 0.98 | 3.20 | (0.61 -16.64) | .17 |
| Relapse/PIF | 2.85 | (1.73 -4.68) | < .0001 | 1.16 | (0.63 -2.13) | 0.64 | 9.29 | (3.23 -26.70) | < .0001 |
| t(9;22) | 0.49 | (0.30 -0.82) | .006 | — | — | — | 0.33 | (0.11 -1.00) | .05 |
| Time from diagnosis to BMT3-150 | 1.33 | (1.08 -1.63) | .008 | 1.31 | (1.05 -1.63) | 0.009 | — | ||
| HLA-A, -B, or -DRB1 mismatched | 1.76 | (1.10 -2.83) | .02 | 2.28 | (1.26 -4.12) | 0.006 | — | ||
| CMV serology (pat-, don-) | 0.62 | (0.38 -1.00) | .05 | 0.43 | (0.23 -0.80) | 0.008 | — | ||
| Karnofsky score ≥ 90 | — | — | 0.41 | (0.23 -0.74) | 0.003 | — | |||
| Cell dose: | |||||||||
| TCD | — | — | 0.45 | (0.18 -1.17) | 0.10 | — | |||
| non-TCD | — | — | 0.79 | (0.64 -0.96) | 0.02 | — | |||
| Parameter . | Disease-free survival . | Treatment-related mortality . | Relapse . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| RR . | 95% Cl . | Pvalue . | RR . | 95% Cl . | P value . | RR . | 95% Cl . | P value . | |
| First remission | 1.00 | NA | 1.00 | NA | 1.00 | NA | |||
| CR 2/3 | 1.38 | (0.64 -2.97) | .40 | 1.01 | (0.42-2.44) | 0.98 | 3.20 | (0.61 -16.64) | .17 |
| Relapse/PIF | 2.85 | (1.73 -4.68) | < .0001 | 1.16 | (0.63 -2.13) | 0.64 | 9.29 | (3.23 -26.70) | < .0001 |
| t(9;22) | 0.49 | (0.30 -0.82) | .006 | — | — | — | 0.33 | (0.11 -1.00) | .05 |
| Time from diagnosis to BMT3-150 | 1.33 | (1.08 -1.63) | .008 | 1.31 | (1.05 -1.63) | 0.009 | — | ||
| HLA-A, -B, or -DRB1 mismatched | 1.76 | (1.10 -2.83) | .02 | 2.28 | (1.26 -4.12) | 0.006 | — | ||
| CMV serology (pat-, don-) | 0.62 | (0.38 -1.00) | .05 | 0.43 | (0.23 -0.80) | 0.008 | — | ||
| Karnofsky score ≥ 90 | — | — | 0.41 | (0.23 -0.74) | 0.003 | — | |||
| Cell dose: | |||||||||
| TCD | — | — | 0.45 | (0.18 -1.17) | 0.10 | — | |||
| non-TCD | — | — | 0.79 | (0.64 -0.96) | 0.02 | — | |||
RR indicates relative risk; Cl, confidence interval; NA, not applicable; CR, complete remission; PIF, primary induction failure; CMV, cytomegalovirus; TCD, T-cell depletion.
RR, expressed per year.